Comparative protection of two different commercial vaccines against Yersinia ruckeri serotype O1 and biotype 2 in rainbow trout (Oncorhynchus mykiss)

S. Deshmukh; M. K. Raida; Inger Dalsgaard; J. K. Chettri; P. W. Kania; K. Buchmann

doi:10.1016/j.vetimm.2011.12.014

Comparative protection of two different commercial vaccines against Yersinia ruckeri serotype O1 and biotype 2 in rainbow trout (Oncorhynchus mykiss)

S. Deshmukh, M. K. Raida, Inger Dalsgaard, J. K. Chettri, P. W. Kania, K. Buchmann

University of Copenhagen

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Differentially extended specific protection by two commercial vaccines against Yersinia ruckeri serotype O1 biotype 2 was studied following 30s immersion exposure. Rainbow trout were challenged intra-peritoneally (i.p.) with Y. ruckeri serotype O1, biotype 2 (≈106 to 107CFU/fish) at 4, 6 and 8 months after vaccination with vaccines containing either biotype 1 (AquaVac® ERM) or both biotypes 1 and 2 (AquaVac® RELERA™). The specific pattern of vaccine-mediated protection was evaluated by relative percentage survival (RPS) analysis at 4 and 6 months post-vaccination and by obtaining gross pathological observations at 4 and 8 months respectively. We determined specific significant and superior protection in terms of increased survivability in AquaVac® RELERA™ vaccinated fish and observed correspondingly fewer pathological changes. The challenge trials indicated a longer protection for at least 6 months without any booster vaccination. A specific and adaptive response induced by AquaVac® RELERA™ vaccine against Y. ruckeri biotype 2 was clearly indicated. In addition, some degree of cross protection rendered by AquaVac® ERM containing biotype 1 during infection with Y. ruckeri biotype 2 was also noted.

Original language	English
Journal	Veterinary Immunology and Immunopathology
Volume	145
Issue number	1-2
Pages (from-to)	379-385
ISSN	0165-2427
DOIs	https://doi.org/10.1016/j.vetimm.2011.12.014
Publication status	Published - 2012

Keywords

RPS
Yersinia ruckeri serotype O1, biotype 2
Rainbow trout
Pathology
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vetimm.2011.12.014

OpenUrl availability

Full text

Cite this

@article{1b4ecf28e51f4ffe94762bc44ffdb4bc,

title = "Comparative protection of two different commercial vaccines against Yersinia ruckeri serotype O1 and biotype 2 in rainbow trout (Oncorhynchus mykiss)",

abstract = "Differentially extended specific protection by two commercial vaccines against Yersinia ruckeri serotype O1 biotype 2 was studied following 30s immersion exposure. Rainbow trout were challenged intra-peritoneally (i.p.) with Y. ruckeri serotype O1, biotype 2 (≈106 to 107CFU/fish) at 4, 6 and 8 months after vaccination with vaccines containing either biotype 1 (AquaVac{\textregistered} ERM) or both biotypes 1 and 2 (AquaVac{\textregistered} RELERA{\texttrademark}). The specific pattern of vaccine-mediated protection was evaluated by relative percentage survival (RPS) analysis at 4 and 6 months post-vaccination and by obtaining gross pathological observations at 4 and 8 months respectively. We determined specific significant and superior protection in terms of increased survivability in AquaVac{\textregistered} RELERA{\texttrademark} vaccinated fish and observed correspondingly fewer pathological changes. The challenge trials indicated a longer protection for at least 6 months without any booster vaccination. A specific and adaptive response induced by AquaVac{\textregistered} RELERA{\texttrademark} vaccine against Y. ruckeri biotype 2 was clearly indicated. In addition, some degree of cross protection rendered by AquaVac{\textregistered} ERM containing biotype 1 during infection with Y. ruckeri biotype 2 was also noted.",

keywords = "RPS, Yersinia ruckeri serotype O1, biotype 2, Rainbow trout, Pathology, Vaccine",

author = "S. Deshmukh and Raida, \{M. K.\} and Inger Dalsgaard and Chettri, \{J. K.\} and Kania, \{P. W.\} and K. Buchmann",

year = "2012",

doi = "10.1016/j.vetimm.2011.12.014",

language = "English",

volume = "145",

pages = "379--385",

journal = "Veterinary Immunology and Immunopathology",

issn = "0165-2427",

publisher = "Elsevier",

number = "1-2",

}

Comparative protection of two different commercial vaccines against Yersinia ruckeri serotype O1 and biotype 2 in rainbow trout (Oncorhynchus mykiss). / Deshmukh, S.; Raida, M. K.; Dalsgaard, Inger et al.
In: Veterinary Immunology and Immunopathology, Vol. 145, No. 1-2, 2012, p. 379-385.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Comparative protection of two different commercial vaccines against Yersinia ruckeri serotype O1 and biotype 2 in rainbow trout (Oncorhynchus mykiss)

AU - Deshmukh, S.

AU - Raida, M. K.

AU - Dalsgaard, Inger

AU - Chettri, J. K.

AU - Kania, P. W.

AU - Buchmann, K.

PY - 2012

Y1 - 2012

N2 - Differentially extended specific protection by two commercial vaccines against Yersinia ruckeri serotype O1 biotype 2 was studied following 30s immersion exposure. Rainbow trout were challenged intra-peritoneally (i.p.) with Y. ruckeri serotype O1, biotype 2 (≈106 to 107CFU/fish) at 4, 6 and 8 months after vaccination with vaccines containing either biotype 1 (AquaVac® ERM) or both biotypes 1 and 2 (AquaVac® RELERA™). The specific pattern of vaccine-mediated protection was evaluated by relative percentage survival (RPS) analysis at 4 and 6 months post-vaccination and by obtaining gross pathological observations at 4 and 8 months respectively. We determined specific significant and superior protection in terms of increased survivability in AquaVac® RELERA™ vaccinated fish and observed correspondingly fewer pathological changes. The challenge trials indicated a longer protection for at least 6 months without any booster vaccination. A specific and adaptive response induced by AquaVac® RELERA™ vaccine against Y. ruckeri biotype 2 was clearly indicated. In addition, some degree of cross protection rendered by AquaVac® ERM containing biotype 1 during infection with Y. ruckeri biotype 2 was also noted.

AB - Differentially extended specific protection by two commercial vaccines against Yersinia ruckeri serotype O1 biotype 2 was studied following 30s immersion exposure. Rainbow trout were challenged intra-peritoneally (i.p.) with Y. ruckeri serotype O1, biotype 2 (≈106 to 107CFU/fish) at 4, 6 and 8 months after vaccination with vaccines containing either biotype 1 (AquaVac® ERM) or both biotypes 1 and 2 (AquaVac® RELERA™). The specific pattern of vaccine-mediated protection was evaluated by relative percentage survival (RPS) analysis at 4 and 6 months post-vaccination and by obtaining gross pathological observations at 4 and 8 months respectively. We determined specific significant and superior protection in terms of increased survivability in AquaVac® RELERA™ vaccinated fish and observed correspondingly fewer pathological changes. The challenge trials indicated a longer protection for at least 6 months without any booster vaccination. A specific and adaptive response induced by AquaVac® RELERA™ vaccine against Y. ruckeri biotype 2 was clearly indicated. In addition, some degree of cross protection rendered by AquaVac® ERM containing biotype 1 during infection with Y. ruckeri biotype 2 was also noted.

KW - RPS

KW - Yersinia ruckeri serotype O1, biotype 2

KW - Rainbow trout

KW - Pathology

KW - Vaccine

U2 - 10.1016/j.vetimm.2011.12.014

DO - 10.1016/j.vetimm.2011.12.014

M3 - Journal article

SN - 0165-2427

VL - 145

SP - 379

EP - 385

JO - Veterinary Immunology and Immunopathology

JF - Veterinary Immunology and Immunopathology

IS - 1-2

ER -

Comparative protection of two different commercial vaccines against Yersinia ruckeri serotype O1 and biotype 2 in rainbow trout (Oncorhynchus mykiss)

Abstract

Keywords

UN SDGs

Access to Document

OpenUrl availability

Fingerprint

Cite this